Respiratory Diagnostics Market Worth $ 7.45 Billion By 2021

Summary

• The global Respiratory Diagnostics Market is projected to reach USD 7.45 Billion by 2021 from USD 5.24 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021.

The reportRespiratory Diagnostics Market provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.

The global Respiratory Diagnostics Marketis projected to reach USD 7.45 Billion by 2021 from USD 5.24 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021.

Ask for PDF Brochure: - Respiratory Diagnostics Market

Major factors driving the market growth are increasing prevalence of respiratory diseases, growing geriatric population, and technological advancements in respiratory diagnostic systems. On the other hand, rising healthcare costs and reimbursement concerns are the major factors restraining the growth of the respiratory diagnostics market. High potential emerging markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore offer significant growth opportunities for the key players in the respiratory diagnostics market.

The global respiratory diagnostics market is segmented on the basis of product and service, test type, disease, end user, and region. On the basis of product and service, the respiratory diagnostics market is segmented into instruments and devices, assays and reagents, and software and services. The instruments and devices segment is expected to account for the largest share of the respiratory diagnostics market in 2016. The continuous requirement of diagnostic instruments and devices in laboratories, point-of-care, and home care is a major factor driving the uptake of instruments and devices.

On the basis of test type, the respiratory diagnostics market is broadly classified into mechanical tests, imaging tests, traditional diagnostic tests, and molecular diagnostic tests. In 2016, the traditional diagnostic tests segment is expected to account for the largest share of the respiratory diagnostics market. The large share of this segment is primarily attributed to the quick turnaround time of these tests.

On the basis of disease, the respiratory diagnostics market is segmented into asthma, chronic obstructive pulmonary disease, lung cancer, tuberculosis, and other diseases. The tuberculosis segment is expected to account for the largest share of the respiratory diagnostics market in 2016. The large share of this segment is primarily attributed to the increase in tobacco smoking and growing air pollution levels.

On the basis of end user, the respiratory diagnostics market is categorized into hospital/clinical laboratories, reference laboratories, physician offices, and other end users (including blood banks, point-of-care testing, patient self-testing, home health agencies, nursing homes, and local public health laboratories). In 2016, the hospital/clinical laboratories segment is expected to account for the largest share of the global respiratory diagnostics market. Most respiratory disease diagnostics are carried out in hospitals as they are complex in nature and require technologically advanced devices; this is driving the respiratory diagnostics market for hospital/clinical laboratories.

North America is expected to account for the largest share of the global respiratory diagnostics market in 2016, followed by Europe. The growth of the respiratory diagnostics market in North America is majorly driven by the rising prevalence of respiratory diseases and growing geriatric population in the region. Other factors supporting the growth of this market include the presence of an advanced healthcare system and strong distribution channels for respiratory diagnostic products in North America.

Request for Sample Pages: - Respiratory Diagnostics Market

The respiratory diagnostics market is dominated by established players such as Philips Healthcare (Netherlands), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Alere, Inc. (U.S.).